CZ Biomed Corporation
A Biotechnology Company
Skip to content
  • Home
  • Products
  • Research
  • News
  • About Us
  • Contact Us

News

July 17, 2017 8:27 a.m. ET

Kocal Consulting Corporation Announces Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment

November 30, 2016

Kocal Consulting Corporation Celebrates New Consulting Agreement with CZ Biomed Corp to Help Deliver Real Value to Bio-Pharm World

November 11, 2015

CZ BioMed Corp. Announces 2.5 Year Survival of Stage 4 Colon Cancer Patient.
Cancer Free After RVLYSIS

August 26, 2013

CZ BioMed Corp. Announces Successful Reduction of Prostate Cancer Tumors
More Than 50% Using PRO-RVLYSIS®

August 16, 2012

CZ BioMed Corp. Announces Licensing of Key U.S. Patent From The University of Texas Health Science Center at San Antonio Regarding the Use of Respiratory Syncytial Virus (RSV) for Anti-Cancer Oncolytic Treatments

January 25, 2012

Prostate Cancer Trials Underway Overseas PRO-RVLYSIS(R) CZ BioMed Corp.

September 22, 2011

Prostate Cancer Cure United States Patent Application – CZ BioMed Corp.

September 8, 2011

PROGRESS IN PANCREATIC CANCER CURE RESEARCH PANRVLYSIS®

Aug 23, 2011

CZ BioMed Corp. Names Internationally Renowned Dr. Ronald E. Wheeler, M.D. as Medical Director of its Scientific and Medical Advisory Boards

May 3, 2011

BREAST CANCER CURE INTERNATIONAL PATENT APPLICATION # PCT/US2011/000602 CZ BioMed Corp.

Oct 12, 2010 12:23 ET

Research for Cancer Cure — RVLYSIS® CZ BioMed Corp.

  • U.S. Patent

  • BIO 2017

  • National Cancer Conference

     
  • Latest News

    • Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment July 17, 2017
  • RSS Cancer Research News

    • One Year Anniversary of Cancer Moonshot Reignition Brings Progress and Opportunity February 3, 2023
      American Cancer Society and ACS CAN Continue Commitment to End Cancer As We Know It, For Everyone
    • American Cancer Society’s BrightEdge Receives $1.25 Million Grant from WoodNext Foundation to Launch Entrepreneurship Fellows Program February 1, 2023
      Program to support and fund scientific founders and their early-stage companies among American Cancer Society-affiliated postdoctoral and early career researchers
    • Suicide Risk Higher Among Individuals with Cancer, New Study Shows January 20, 2023
    • American Cancer Society Releases Latest Cancer Statistics, Launches Initiative to Address Prostate Cancer Resurgence and Disparities January 12, 2023
    • La Sociedad Americana Contra El Cáncer publica las últimas estadísticas sobre el cáncer, lanza una iniciativa para abordar la recurrencia y las inequidades del cáncer de próstata January 12, 2023
  • Published on Oct 13, 2016  


    Robert Andtbacka, MD, CM of the Huntsman Cancer Institute, Salt Lake City, UT discusses the use of oncolytic viruses at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria.

  • Health Care Forum “War on Cancer” (March 30th 2017-Singapore)

     
  • Announcements

    • Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment
    • Partnerships with Bio-pharmaceutical Leaders
    • Oncolytic Virus Reduces Prostate Cancer
  • Related Articles

    Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferondependent antiviral defense - Research Article (Biomed Central)

    Childhood virus RSV shows promise against adult cancer. - Science Daily

    CZ BioMed licenses children’s virus turned anti-cancer agent. - San Antonio Business Journal
CZ Biomed Corporation
Proudly powered by WordPress.